Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 138

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 138
---
 the gross proceeds from the sale of the
maximum number of securities being offered in this prospectus.

We
have engaged Maxim Group LLC to act as our exclusive placement agent to solicit offers to
purchase the securities offered by this prospectus. The placement agent is not purchasing
or selling any securities, nor is it required to arrange for the purchase and sale of any
specific number or dollar amount of securities, other than to use its “reasonable best
efforts” to arrange for the sale of the securities by us. Therefore, we may not sell
the entire number of securities being offered. Investors purchasing securities offered hereby
will have the option to execute a securities purchase agreement with us. Investors who do
not enter into a securities purchase agreement shall rely solely on this prospectus in connection
with the purchase of our securities in this offering. The placement agent may engage one
or more subagents or selected dealers in connection with this offering.

The placement agency agreement
provides that the placement agent’s obligations are subject to conditions contained in the placement agency agreement.

We will deliver the securities
being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. There
is no arrangement for funds to be received in escrow, trust or similar arrangement and the Depositary Shares (or Pre-Funded Warrants in
lieu thereof) will be offered at a fixed price and are expected to be issued in a single closing. We expect to deliver the securities
being offered pursuant to this prospectus on or about , 2025.

Placement Agent Fees, Commissions and Expenses

Upon
the closing of this offering, we will pay the placement agent a cash transaction fee equal to 7% of the aggregate gross cash proceeds
to us from the sale of the securities in the offering. In addition, we will reimburse the placement agent for its accountable out-of-pocket
expenses incurred in connection with this offering, including the fees and expenses of the counsel for the placement agent, up to $100,000.
We have paid the placement agent an expense advance of $25,000 upon signing of an engagement agreement, or the Cash Advance. Any portion
of the Cash Advance not applied to accountable out-of-pocket expenses incurred by the placement agent shall be returned back to us in
accordance with FINRA Rule 5110(f)(2)(C). We have also agreed to pay to the placement agent a fee equal to the Nominal Value Amount.

The following table shows
the public offering